Audit: QRS - Chlorogenic Acid for Health & Longevity

Audit conducted on 18/09/2026 13:53 using AI4L / Opus 5

Iterations

Summary

Items	Count
Total	93
Passed	84
Failed	0
N/A	9
Pass Rate	100.00%

• Total = Passed + Failed + N/A
• Pass Rate = Passed / (Passed + Failed) × 100
• N/A items are excluded from the pass rate calculation

---

1. General Rules

#	Description	Result	Comments
1.1	Every claim, magnitude, label, recommendation, and statement in the QRS is literally supported by content in the source ER.	🟢	Spot-checked every span against the ER: protocol doses (ER 398), timing (ER 404), split dosing (ER 408), time-to-effect (ER 449), gates (ER 344-371), tiers (ER 155-241, 266-324), monitoring table (ER 479-490) and qualitative markers (ER 494-498) all trace to ER text.
1.2	Where the ER uses cautious phrasing (“not formally studied”, “None documented in human trials to date”, “theoretical concern”, “data are limited”), the QRS uses the same phrasing.	🟢	No cautious ER phrasing is dropped or hardened; the conflicted/null readings the ER gives for cognition and liver fat are carried into the lede as “failed in people”.
1.3	The QRS never strengthens an ER claim (e.g., “not formally studied” → “not required”) or softens one (e.g., “do not use during pregnancy” → “use with caution during pregnancy”).	🟢	No strengthening or softening found. “Pregnancy and breastfeeding” stays in Contraindications, not Key Interactions; “injection-site induration with the investigational injectable form” keeps the route qualifier so it is not read as an oral risk.
1.4	The QRS does not relabel an ER fact under a different decision category. A “Benefit-Modifying Factor” from ER section is not surfaced as a “Caution”; a “Risk-Modifying Factor” is not surfaced as a “Side Effect”; etc.	🟢	Tier membership matches the ER exactly for all four benefit tiers and all three populated risk tiers; no Benefit- or Risk-Modifying Factor (ER 244-258, 327-339) is surfaced as a gate item.
1.5	PubMed IDs, study citations, expert names, clinical trial identifiers (NCT*), and brand names appear in the QRS only if they appear in the source ER for the same fact.	🟢	Only one named source appears — “Examine” in action_1_sub — and the ER states the same fact and attribution at line 398. No PMIDs, NCT IDs or study citations.
1.6	The QRS does not introduce new attributions.	🟢	No attribution appears in the QRS that is absent from the ER.

2. Focus, Tone & Audience

#	Description	Result	Comments
2.1	The QRS follows the tone of the ER, which is determined by the ER’s own language, phrasing, and framing.	🟢	Matches the ER’s measured, skeptical register throughout.
2.2	The tone of the QRS is simultaneously expert, accessible, objective, and data-driven, but also empowering and encouraging	🟢	Expert and data-driven (doses, thresholds, biomarker ranges) while remaining accessible.
2.3	The QRS reads as a trusted, knowledgeable guide rather than a prescriptive doctor	🟢	Presents the ER’s protocol and monitoring as evidence, not as instruction to an individual.
2.4	The QRS avoids language that implies medical or clinical advice	🟢	No clinical directives; the footer disclaimer is the unmodified template text.
2.5	The QRS “presents information” instead of “providing guidance”, “recommending”, or “advising”	🟢	No “recommend”, “advise” or “suggest” anywhere in the document.
2.6	The QRS never addresses “the reader” directly — it presents evidence, not guidance	🟢	No second-person pronouns anywhere in the document.
2.7	The QRS is written in plain language, avoiding unnecessary medical jargon	🟢	Technical terms are limited to biomarker and outcome labels the ER itself uses as headings; no avoidable jargon.
2.8	Information is presented in a concise and very compact manner	🟢	Every item is reduced to the key fact; no section carries explanatory prose.
2.9	It DOES NOT address the reader directly	🟢	Confirmed — no direct address.
2.10	The target audience is health- and longevity-oriented adults who are risk-aware, proactive, and actively seeking to optimize health or apply the intervention under review.	🟢	Content assumes a reader who will measure baselines, source a standardized extract and track ten biomarkers.
2.11	The target audience is willing to employ lifestyle and behavioral changes as well as follow protocols that may be inconvenient, costly, or require effort.	🟢	Protocol and monitoring cadence assume willingness to test, separate doses from iron, and re-measure over months.
2.12	The document is NOT written for the general population, who are unwilling to employ lifestyle and behavioral changes or follow protocols that may be inconvenient, costly, or require effort.	🟢	Not pitched at the general population; the ten-marker panel and twelve-week retest schedule presuppose effort.
2.13	Framing, takeaways, and risk/benefit weighting throughout the document reflect this audience, including where an intervention’s signal for the average person differs from its signal for this audience.	🟢	The lede makes the audience-relevant discrimination explicit: effects appear only where starting values are above target.
2.14	The document’s own voice frames usage in longevity terms, not “anti-aging” (e.g., “anti-aging clinics”, “anti-aging community”, “anti-aging medicine”). Proper names that contain “anti-aging” (e.g., “American Academy of Anti-Aging Medicine”) are quoted verbatim.	🟢	No occurrence of “anti-aging”; the ER’s longevity framing is preserved.
2.15	The document’s own voice uses formal clinical and scientific terminology, not colloquial or consumer-grade language (e.g., “oral medication” not “pill(s)”; “oral” / “administered orally” not “taken by mouth” / “given by mouth”; “injection” not “shot”; “adverse event” not “bad reaction”). This holds on EVERY surface, including the QRS lede — the stricter plain-language bar (see 2.7) does not license lay phrasing for route of administration. Direct quotes from sources are exempt.	🟢	No colloquial or consumer-grade substitutions; route of administration is expressed as “injectable form” and “oral” wording follows the ER.

3. Template Integrity

#	Description	Result	Comments
3.1	The following labels and headings on the QRS are fixed and not modified: Card and section headings: “Protocol”, “Time to effect”, “Benefits”, “Risk & Side Effects”, “Monitoring”, “Qualitative Assessment”; Gate headings: “Contraindications”, “Key Interactions”; Tier labels: “High”, “Medium”, “Low”, “Speculative”; Table column headers in Monitoring: “Marker”, “Target”, “Why”	🟢	All fixed strings verified against the template: “Protocol”, “Time to effect”, “Benefits”, “Risk & Side Effects”, “Monitoring”, “Qualitative Assessment”, “Contraindications”, “Key Interactions”, the four tier labels, and “Marker”/”Target”/”Why”.
3.2	All “…” from the [qrs_template] are present in the the QRS.	🟢	All 34 fixed template variables are present; the repeatable marker_#* pattern is expanded to marker_1..10 and qualitative_item# to qualitative_item_1..5.
3.3	Spans that are not addressed in a checklist item are left unchanged	🟢	The three website=”…” spans are untouched, and the head/CSS block is byte-identical to the template apart from page_title.

4. Formatting

#	Description	Result	Comments
4.1	When the source ER section is empty, the QRS uses the ER’s own empty-state phrasing verbatim. Typical phrasings are “None documented in human trials to date” and “Not formally studied”	N/A	No source ER section is empty, and the ER uses neither “None documented in human trials to date” nor “Not formally studied” anywhere. The ER’s High risk tier carries prose rather than items and is handled under 13.5.
4.2	Where the ER presents a bulleted item as “Label: content”, the QRS uses the ER’s bold label verbatim as the cell or row label.	🟢	Bold ER labels are reused verbatim: “Standard protocol — standardized extract”, “Best time of day”, “Single versus split dosing”, and all five qualitative-marker labels.
4.3	Labels are not paraphrased, abbreviated, or invented.	🟢	No label is paraphrased or abbreviated; the ten monitoring marker names are copied exactly from the ER table.
4.4	The QRS DOES NOT use emoji indicators (no 🟩, 🟥, 🟨, etc.). Color and emphasis are conveyed through CSS and bold labels.	🟢	Zero emoji characters in the file; tiers are carried by bold labels and CSS only.
4.5	The QRS is designed to render on one A4 page. Any section that has more content in the ER than fits the per-section budget is condensed by the LLM, not extended onto a second page.	🟢	Every section is condensed to bare key facts — explanations, effect sizes and mechanisms are stripped throughout. The item counts that remain (ten interactions, ten markers) are mandated by 9.2 and 14.2.

5. Metadata

#	Description	Result	Comments
5.1	The metadata is placed inside a single HTML comment that is the first element after “<!doctype html>” and before any other comment, head, or body content.	🟢	The metadata comment spans lines 2-14, immediately after “<!doctype html>” on line 1 and before <html>.
5.2	Inside that HTML comment the YAML block is delimited by a line “—” opening and a line “—” closing. Text before the opening “—” is permitted but is not parsed as YAML.	🟢	Opening “—” at line 3 and closing “—” at line 13; the preceding “QRS — Metadata” text sits outside the YAML block.
5.3	The metadata is not visible in any rendered view of the QRS and is not surfaced by any other element on the sheet.	🟢	Enclosed in an HTML comment and not echoed by any visible element.
5.4	All frontmatter values are trimmed: no leading or trailing whitespace, no surrounding quotes unless the value contains a colon, bracket, or leading special character that requires YAML quoting.	🟢	All values trimmed; only duration: “00:03” is quoted, which YAML requires because the value contains a colon.
5.5	The filename of the source ER is stated as “er_filename: [er_filename]”	🟢	er_filename: chlorogenic_acid_2026-0918-0846_Opus_ER.md — matches the ER’s own frontmatter filename field.
5.6	Version of the QRS.md file used to create the document is stated as “qrs_prompt_version: [Version of QRS.md]”	🟢	qrs_prompt_version: 26.9.11 — matches the QRS.md version badge.
5.7	Creation date and time of the document is stated as “qrs_creation_date: [YYYY-MMDD-HHMM]” (e.g., 2026-0501-1430)	🟢	qrs_creation_date: 2026-0918-1333 — correct YYYY-MMDD-HHMM form.
5.8	The nickname of the AI used to create the document is stated as “qrs_creator_ai_nickname: [qrs_creator_ai_nickname]”	🟢	qrs_creator_ai_nickname: Opus
5.9	The nickname of the AI is just a single word model name without version, etc. (e.g., Opus, Sonnet, Grok, Gemini, ChatGPT)	🟢	Single word, no version or qualifier.
5.10	The full name of the AI used to create the document is stated as “qrs_creator_ai_fullname: [qrs_creator_ai_fullname]”	🟢	qrs_creator_ai_fullname: Opus 5
5.11	The full name of the AI consists of the [qrs_creator_ai_nickname] and the model version number and no additional qualifier (e.g., Opus 4.6, Sonnet 3.2, Grok 4.5, Gemini 3.1, ChatGPT 5.4)	🟢	Nickname plus version number only; no context-window or other qualifier appended.
5.12	The filename of the document is stated as “qrs_filename: [filename of this document]”	🟢	qrs_filename: chlorogenic_acid_2026-0918-0846_Opus_QRS.html — matches the file on disk.
5.13	All frontmatter values are trimmed: no leading or trailing whitespace, no surrounding quotes unless the value contains a colon, bracket, or leading special character that requires YAML quoting.	🟢	Confirmed for all nine frontmatter keys.

6. Page Title & Header

#	Description	Result	Comments
6.1	[page_title] is set to the [canonical_topic] of the ER frontmatter followed by “ - Quick Reference Sheet” (e.g., “Intervention - Quick Reference Sheet”). The [canonical_topic] is HTML-entity-encoded as needed (e.g., & for &)	🟢	Title reads “Chlorogenic Acid for Health & Longevity - Quick Reference Sheet” — canonical_topic with the ampersand correctly entity-encoded.
6.2	[header_topic] is set to the [canonical_topic] of the ER frontmatter, with HTML entities encoded as needed (e.g., & for &)	🟢	header_topic reads “Chlorogenic Acid for Health & Longevity”.
6.3	[header_subline_date] is set to [qrs_creation_date reformatted as MM/DD/YYYY]	🟢	header_subline_date is 09/18/2026, the MM/DD/YYYY form of qrs_creation_date 2026-0918-1333.
6.4	[header_subline_model] is set to [qrs_creator_ai_fullname]	🟢	header_subline_model is “Opus 5”, matching qrs_creator_ai_fullname.
6.5	No additional header content appears: no badge, version stamp, AKA / alternate names line, source-AI attribution, audit date, or QRS variant marker.	🟢	Header markup is identical to the template; no badge, AKA line, version stamp or audit date.

7. At-A-Glance Section

#	Description	Result	Comments
7.1	[at_a_glance] is dense, execution-oriented summary of the ER Conclusion section	🟢	Condenses the ER Conclusion (ER 519-523) into what moves, for whom, what failed, and the two practical caveats.
7.2	[at_a_glance] is no longer than 60 words	🟢	Exactly 60 words — at, not over, the limit.
7.3	Every fact in [at_a_glance] is supported by a distinct passage in the ER.	🟢	Each clause traces to a distinct ER passage: ER 519 (main compound, the four outcomes, above-target framing, the three failed claims), ER 521 (iron binding), ER 521/436 (half of products off-label).
7.4	It DOES NOT use acronyms or technical classifications that require specialist knowledge, uses plain-language terms instead	🟢	No acronyms and no specialist classifications; uses “blood sugar”, “green coffee extract” and “animal work” in place of technical terms.
7.5	It DOES NOT cite specific trials (names, years, sample sizes, p-values)	🟢	No trial names, years, sample sizes or p-values.
7.6	It DOES NOT cite effect sizes, relative risks, or statistical results	🟢	No effect sizes, confidence intervals or relative risks.

8. Contraindications

#	Description	Result	Comments
8.1	The section is derived from the ER Key Interactions & Contraindications section	🟢	Drawn from the ER’s “Populations who should avoid Chlorogenic Acid” list (ER 364-371) inside Key Interactions & Contraindications.
8.2	[stop_items] represent the Contraindications from the ER	🟢	All six ER contraindications are present, none added.
8.3	Individual [stop_items] are formatted as <li></li>	🟢	Six discrete <li> elements inside the stop_items span.
8.4	Items are as concise as possible. No trailing explanations, no elaborations, no mechanistic rationale, no attributions, no citations, no study details. No content after an em-dash, en-dash, or hyphen-dash (e.g., “— dose reduction required”, “— reduced efficacy”) — these trailing clauses are stripped. Just the key fact.	🟢	Trailing clauses stripped correctly: ER 368 “— no controlled safety data exist at supplemental doses” and ER 371 “, in whom no dose has been studied” are both removed.
8.5	Parenthetical qualifiers from the ER bullet — time windows, severity classes, threshold values, clinical staging — ARE preserved as part of the item, kept as concise as possible (shortened or trimmed where needed to fit the one-page budget, but never dropped entirely).	🟢	Decision-relevant qualifiers preserved: “ferritin below 30 ng/mL”, “(systolic below 100 mmHg)”, “above 15 μmol/L with low folate or vitamin B12”, “under 18 years”.
8.6	When the ER uses ranking notation inside parens (e.g., “>” for severity ordering) that depends on an explanatory phrase to interpret, normalize the items to a plain comma-separated list rather than carrying through the bare symbol.	N/A	The ER uses no ranking notation inside parentheses in this section.
8.7	The section is left empty ONLY IF the ER’s Key Interactions & Contraindications section identifies no population, condition, or scenario for which the intervention should be avoided, deferred, or used only under specialist supervision.	🟢	The section is populated, and the ER does identify populations that should avoid the intervention, so the restriction is not engaged.
8.8	If the section is left empty, an HTML comment inside the [stop_items] span records the ER basis for the absence, naming or quoting the ER text relied on. E.g.	N/A	The section is not empty.

9. Key Interactions

#	Description	Result	Comments
9.1	The section is derived from the ER Key Interactions & Contraindications section	🟢	Drawn from the ER’s ten interaction bullets (ER 344-362).
9.2	[caution_items] represent the Key Interactions from the ER, excluding any that are already listed as Contraindications	🟢	All ten ER interactions are represented, with no overlap into the contraindication list.
9.3	Individual [caution_items] are formatted as <li></li>	🟢	Ten discrete <li> elements inside the caution_items span.
9.4	Items are as concise as possible. No trailing explanations, no elaborations, no mechanistic rationale, no attributions, no citations, no study details. No content after an em-dash, en-dash, or hyphen-dash (e.g., “— dose reduction required”, “— reduced efficacy”) — these trailing clauses are stripped. Just the key fact.	🟢	Em-dash glosses stripped while the substance is kept: ER 350 “— those that slow blood clotting” and ER 354 “— drugs that shut off stomach acid” are removed, and ER 362 “Other interventions —” is replaced by the substantive clause rather than the empty category word.
9.5	Parenthetical qualifiers from the ER bullet — example drug lists, time windows, severity classes, threshold values, clinical staging — ARE preserved as part of the item, kept as concise as possible (shortened or trimmed where needed to fit the one-page budget, but never dropped entirely).	🟢	Every parenthetical example-drug list is preserved intact across all nine drug and supplement classes.
9.6	When the ER uses ranking notation inside parens (e.g., “>” for severity ordering) that depends on an explanatory phrase to interpret, normalize the items to a plain comma-separated list rather than carrying through the bare symbol.	N/A	The ER uses no ranking notation inside parentheses in this section.
9.7	The section is left empty ONLY IF the ER’s Key Interactions & Contraindications section identifies no interaction, additive effect, or exposure that changes how the intervention is used.	🟢	The section is populated, and the ER does identify interactions, so the restriction is not engaged.
9.8	If the section is left empty, an HTML comment inside the [caution_items] span records the ER basis for the absence, naming or quoting the ER text relied on. E.g.	N/A	The section is not empty.

10. Protocol

#	Description	Result	Comments
10.1	The section is derived from the ER Protocol section	🟢	Derived from the ER Therapeutic Protocol section (ER 395-418).
10.2	The three sets of [action] items cover the three most important actionable implementation aspects from the ER Protocol section	🟢	Dose, timing and dose-splitting are the three actionable bullets in that section; the remainder (competing approaches, half-life, genotype, sex, age, baseline, comorbidity) are contextual rather than actionable.
10.3	If less that three distinct actionable implementation aspects are mentioned in the ER the unused sets are left empty and made invisible, not filled with placeholder text or empty-state phrasing.	N/A	The ER provides more than three actionable implementation aspects, so all three sets are used.
10.4	All used [action_#label], [action#value], [action#_sub] items are filled with meaningful content derived from the ER Protocol section.	🟢	All nine action fields carry ER-derived content; action_1_sub keeps the 45-50% standardization and the Examine range from ER 398.

11. Time to Effect

#	Description	Result	Comments
11.1	The three sets of [time] items cover the three most important time-to-effect aspects from the ER	🟢	Blood pressure, fasting glucose and body weight are the three time-to-effect aspects the ER names (ER 449); the acute-vasodilation figure from the same bullet is carried in time_1_sub.
11.2	The sets are picked and ordered by the magnitude of the related benefit	🟢	Order matches the ER High benefit tier order: blood pressure, fasting glucose and insulin, then body weight (ER 155-173).
11.3	If less that three distinct time-to-effect aspects are mentioned in the ER the unused sets are left empty and made invisible, not filled with placeholder text or empty-state phrasing.	N/A	The ER provides three distinct time-to-effect aspects, so all three sets are used.
11.4	All used [time_#label], [time#value], [time#_sub] items are filled with meaningful content derived from the ER.	🟢	All nine time fields are populated; 4-12 weeks and 8-12 weeks both trace to ER 449.
11.5	If the ER does not provide any information on time to effect, the section is removed completely from the Protocol Panel	N/A	The ER does provide time-to-effect information, so the section is retained.

12. Benefits

#	Description	Result	Comments
12.1	The section is derived from the ER Expected Benefits section	🟢	Derived from the ER Expected Benefits section (ER 150-241).
12.2	Key variables are [benefits_high], [benefits_medium], [benefits_low], [benefits_speculative]	🟢	All four benefit variables are present and populated.
12.3	Items are as concise as possible. No explanations, no elaborations, no effect sizes, no qualifiers, no attributions, no citations, no study details, no mechanistic explanations, etc. Just the key fact.	🟢	Each tier is a semicolon-separated list of bare outcome names; no magnitudes, confidence intervals, trial details or mechanisms survive.
12.4	Parenthetical content — including effect sizes, sample notes, mechanistic hints, and example studies — is stripped, NOT preserved.	🟢	No parenthetical content carried over; the ER’s “⚠️ Conflicted” markers are also dropped, as 4.4 requires.
12.5	If no items of a specific sub-section (high, medium, low, speculative) are present the respective is set to “display=none”, not filled with “None documented in human trials to date” or similar empty-state phrasing.	N/A	All four ER benefit tiers contain items, so no span needs hiding.

13. Risks

#	Description	Result	Comments
13.1	The section is derived from the ER Potential Risks & Side Effects section	🟢	Derived from the ER Potential Risks & Side Effects section (ER 261-324).
13.2	Key variables are [risks_high], [risks_medium], [risks_low], [risks_speculative]	🟢	All four risk variables are present in the markup.
13.3	Items are as concise as possible. No explanations, no elaborations, no effect sizes, no qualifiers, no attributions, no citations, no study details, no mechanistic explanations, etc. Just the key fact.	🟢	Each tier is a bare list of the ER’s risk headings; no frequencies, grades, trial details or mechanisms survive.
13.4	Parenthetical content — including frequencies, severity grades, sample notes, mechanistic hints, and example studies — is stripped, NOT preserved.	🟢	The parenthetical “(Tissue Hardening)” in the ER heading at line 278 is correctly stripped.
13.5	If no items of a specific sub-section (high, medium, low, speculative) are present the respective is set to “display=none”, not filled with “None documented in human trials to date” or similar empty-state phrasing.	🟢	The ER’s High risk tier contains no items (ER 268), and risks_high is set to style=”display: none” with empty content rather than carrying empty-state prose.

14. Monitoring

#	Description	Result	Comments
14.1	The section is derived from the ER Monitoring section	🟢	Derived from the ER Monitoring Protocol & Defining Success section (ER 473-490).
14.2	All measurable/quantifiable biomarkers from the Monitoring section are listed	🟢	All ten rows of the ER biomarker table are present, with target ranges and rationale strings reproduced exactly.
14.3	[monitoring_cadence] is populated with the monitoring cadence/frequency derived from the ER Monitoring section. It is not left with placeholder text or empty.	🟢	Populated with the ER cadence from line 477, covering blood pressure, fasting glucose, and the twelve-week ferritin/homocysteine/lipid retest.

15. Qualitative Assessment

#	Description	Result	Comments
15.1	The section is derived from the ER Monitoring section	🟢	Derived from the ER qualitative-marker list (ER 492-498).
15.2	All subjective/qualitative biomarkers from the Monitoring section are listed	🟢	All five ER qualitative markers are present with their bold labels verbatim.

Issues 18/09/2026 13:53

Pass rate 100.00%. No issues found.

Issues 18/09/2026 13:44

1. 1.4 — Monitoring cadence shown as time-to-effect: time_2_sub (line 516) states “fasting glucose is checked at four and twelve weeks”, which is the ER’s monitoring schedule (ER line 477), surfaced under the Time-to-Effect panel and duplicated verbatim in monitoring_cadence (line 799).

Fixes 18/09/2026 13:44

1. 1.4 — Monitoring cadence shown as time-to-effect: Replaced time_2_sub with “Fasting glucose changes appear in the same four-to-twelve-week trial window as blood pressure.”, removing the ER monitoring-schedule clause (“fasting glucose is checked at four and twelve weeks”) that duplicated monitoring_cadence.

Issues 18/09/2026 13:38

1. 1.1 / 1.3 / 7.3 — Lifespan claim overstated in lede: [at_a_glance] (line 435) asserts that a “longer life” claim “failed in people”, but the ER states the lifespan evidence is invertebrate-only and that “no human lifespan data exist” (ER line 237); the ER Conclusion offers two branches (“either failed when tested in people or have been tested only in animals and cell cultures”, ER line 519), of which only one applies to lifespan.
2. 13.4 — Parenthetical gloss carried into risk item: [risks_medium] (line 631) uses “injection-site hardening”, which is the ER heading’s parenthetical gloss “(Tissue Hardening)” rather than the stripped term “induration” (ER line 278).

Fixes 18/09/2026 13:38

1. 1.1 / 1.3 / 7.3 — Lifespan claim overstated in lede: Rewrote [at_a_glance] so the lifespan claim is no longer reported as having failed in humans — “Claims of sharper thinking, a healthier liver or longer life failed in people” became “Sharper thinking and a healthier liver failed in people; longer life rests on animal work”, with the opening clause condensed to “Coffee’s main plant compound” to hold the 60-word limit.
2. 13.4 — Parenthetical gloss carried into risk item: Replaced “injection-site hardening” with “injection-site induration” in [risks_medium], using the ER heading’s term rather than its parenthetical gloss.